Compare Bristol-Myers Squibb Co (BMY) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Orion Office REIT Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.95 (market cap $129.94B), while Orion Office REIT Inc trades at $2.78 (market cap $158.01M). The key difference: Bristol-Myers Squibb Co is far larger — about 822.4× Orion Office REIT Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | ONL | |
|---|---|---|
Market Cap | $129.94B | $158.01M |
Sector | Health | Real Estate |
52-Week High | $65.89 | $3.04 |
52-Week Low | $42.60 | $1.93 |
Enterprise Value | $163.92B | $574.95M |
Dividend Yield | 3.96% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
ONL trades at $2.76, up 0.36% today, with a bullish technical signal from moving averages. The company reported a Q2 2026 EPS beat of $0.42 versus -$0.07 expected, but maintains negative net income and ROE. Revenue has declined from $208M in 2022 to $148M in 2025, with a net loss of -$139M. Analyst consensus is split evenly between Buy and Hold.
The outlook remains challenged by persistent losses and declining revenue, though the low P/B of 0.25 suggests asset value. Key risks include high debt and weak profitability. Upside depends on successful portfolio repositioning and a return to sustained earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
